# Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

> **NCT02895061** · NA · COMPLETED · sponsor: **Phramongkutklao College of Medicine and Hospital** · enrollment: 502 (actual)

## Conditions studied

- Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis

## Interventions

- **DRUG:** Alfacalcidol

## Key facts

- **NCT ID:** NCT02895061
- **Lead sponsor:** Phramongkutklao College of Medicine and Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-10
- **Final completion:** 2016-01
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2017-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02895061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02895061, "Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02895061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*